Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity: 2009-2025

Historic Common Equity for Gyre Therapeutics (GYRE) over the last 15 years, with Sep 2025 value amounting to $137.4 million.

  • Gyre Therapeutics' Common Equity rose 39.54% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 39.54%. This contributed to the annual value of $98.4 million for FY2024, which is 721.70% up from last year.
  • Gyre Therapeutics' Common Equity amounted to $137.4 million in Q3 2025, which was up 6.16% from $129.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Common Equity registered a high of $137.4 million during Q3 2025, and its lowest value of -$28.3 million during Q2 2023.
  • For the 3-year period, Gyre Therapeutics' Common Equity averaged around $62.1 million, with its median value being $93.3 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first slumped by 195.82% in 2023, then spiked by 2,699.94% in 2024.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Common Equity stood at $41.1 million in 2021, then surged by 75.76% to $72.2 million in 2022, then plummeted by 121.92% to -$15.8 million in 2023, then soared by 721.70% to $98.4 million in 2024, then surged by 39.54% to $137.4 million in 2025.
  • Its Common Equity stands at $137.4 million for Q3 2025, versus $129.4 million for Q2 2025 and $104.3 million for Q1 2025.